Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.

Suppr

超能文献

作者信息

Powis G

出版信息

Cancer Treat Rev. 1982 Jun;9(2):85-124. doi: 10.1016/s0305-7372(82)80012-1.

DOI:10.1016/s0305-7372(82)80012-1

PMID:6181872

Abstract

摘要

相似文献

Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.

Cancer Treat Rev. 1982 Jun;9(2):85-124. doi: 10.1016/s0305-7372(82)80012-1.

Clinical pharmacokinetics of commonly used anticancer drugs.

Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002.

[Pharmacokinetics of antitumor drugs].

Vopr Onkol. 1983;29(7):3-13.

Sparfosate. A novel biomodulator of 5-fluorouracil.

Cancer Pract. 1999 Jul-Aug;7(4):212-6. doi: 10.1046/j.1523-5394.1999.74011.x.

[Pharmacokinetics of antineoplastic agents (author's transl)].

Bull Cancer. 1979;66(1):39-42.

Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.

Eur J Cancer Clin Oncol. 1981 Nov;17(11):1199-204.

Pharmacokinetic drug interactions of commonly used anticancer drugs.

Clin Pharmacokinet. 1986 May-Jun;11(3):223-35. doi: 10.2165/00003088-198611030-00004.

Pharmacokinetics of anticancer drugs in children.

Drug Metab Rev. 1983;14(5):847-86. doi: 10.3109/03602538308991413.

Physiologically based pharmacokinetic models for anticancer drugs.

Cancer Chemother Pharmacol. 1979;2(2):85-94. doi: 10.1007/BF00254079.

Introduction to 5-fluorouracil modulation.

Cancer Invest. 1990;8(2):257-8. doi: 10.3109/07357909009017575.

引用本文的文献

Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.

Cancer Res. 2020 Feb 15;80(4):868-876. doi: 10.1158/0008-5472.CAN-19-2553. Epub 2019 Nov 26.

Pharmacokinetically guided administration of chemotherapeutic agents.

Clin Pharmacokinet. 2000 Nov;39(5):345-67. doi: 10.2165/00003088-200039050-00004.

Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Clin Pharmacokinet. 1999 Jun;36(6):391-8. doi: 10.2165/00003088-199936060-00001.

Cancer chemotherapy in older adults. A tolerability perspective.

Drugs Aging. 1997 Jan;10(1):34-49. doi: 10.2165/00002512-199710010-00004.

Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Clin Pharmacokinet. 1987 Oct;13(4):205-27. doi: 10.2165/00003088-198713040-00001.

Problems in the use of anticancer drugs in the elderly.

Drugs. 1989 Apr;37(4):551-65. doi: 10.2165/00003495-198937040-00007.

Clinical pharmacology of 5-fluorouracil.

Clin Pharmacokinet. 1989 Apr;16(4):215-37. doi: 10.2165/00003088-198916040-00002.

Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.

Cancer Chemother Pharmacol. 1989;23(6):367-72. doi: 10.1007/BF00435838.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.

Cancer Treat Rev. 1982 Jun;9(2):85-124. doi: 10.1016/s0305-7372(82)80012-1.

Clinical pharmacokinetics of commonly used anticancer drugs.

Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002.

[Pharmacokinetics of antitumor drugs].

Vopr Onkol. 1983;29(7):3-13.

Sparfosate. A novel biomodulator of 5-fluorouracil.

Cancer Pract. 1999 Jul-Aug;7(4):212-6. doi: 10.1046/j.1523-5394.1999.74011.x.

[Pharmacokinetics of antineoplastic agents (author's transl)].

Bull Cancer. 1979;66(1):39-42.

Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.

Eur J Cancer Clin Oncol. 1981 Nov;17(11):1199-204.

Pharmacokinetic drug interactions of commonly used anticancer drugs.

Clin Pharmacokinet. 1986 May-Jun;11(3):223-35. doi: 10.2165/00003088-198611030-00004.

Pharmacokinetics of anticancer drugs in children.

Drug Metab Rev. 1983;14(5):847-86. doi: 10.3109/03602538308991413.

Physiologically based pharmacokinetic models for anticancer drugs.

Cancer Chemother Pharmacol. 1979;2(2):85-94. doi: 10.1007/BF00254079.

Introduction to 5-fluorouracil modulation.

Cancer Invest. 1990;8(2):257-8. doi: 10.3109/07357909009017575.

引用本文的文献

Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.

Cancer Res. 2020 Feb 15;80(4):868-876. doi: 10.1158/0008-5472.CAN-19-2553. Epub 2019 Nov 26.

Pharmacokinetically guided administration of chemotherapeutic agents.

Clin Pharmacokinet. 2000 Nov;39(5):345-67. doi: 10.2165/00003088-200039050-00004.

Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Clin Pharmacokinet. 1999 Jun;36(6):391-8. doi: 10.2165/00003088-199936060-00001.

Cancer chemotherapy in older adults. A tolerability perspective.

Drugs Aging. 1997 Jan;10(1):34-49. doi: 10.2165/00002512-199710010-00004.

Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Clin Pharmacokinet. 1987 Oct;13(4):205-27. doi: 10.2165/00003088-198713040-00001.

Problems in the use of anticancer drugs in the elderly.

Drugs. 1989 Apr;37(4):551-65. doi: 10.2165/00003495-198937040-00007.

Clinical pharmacology of 5-fluorouracil.

Clin Pharmacokinet. 1989 Apr;16(4):215-37. doi: 10.2165/00003088-198916040-00002.

Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.

Cancer Chemother Pharmacol. 1989;23(6):367-72. doi: 10.1007/BF00435838.